RNAZ
Transcode Therapeutics, Inc.
Next earnings ≈ Aug 14, 2026 · est. from filing cadence
$4.97
▲ +9.23%$4.97▼ -37.64%
over 1Y
L $4.55EODHDH $15.23
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+9.2%
1W+9.2%
1M-2.4%
3M-42.9%
YTD-32.8%
1Y-37.6%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 7 analysts
Buy
Mixed signals in the latest filings.
Return on equity -335.4% · latest
Transcode Therapeutics, Inc. shows limited reported revenue, and -335.4% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$6.15M | -$18.6M | -$19.4M | -$15.7M | -$28.0M |
| Net income | -$6.84M | -$17.6M | -$18.5M | -$16.8M | -$34.7M |
| Diluted EPS | -$0.81 | -$1,082.79 | -$3,419.01 | -$1,336.63 | -$52.59 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value-$13.3M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-760.6%
FCF yield-428.4%
Quality & risk
ROIC (est.)-213.9%
Free cash flow-$19.5M
Total debt—
Net cash$17.8M
Piotroski F-Score4/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY-96.1%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — delisting notice (2026-05-22). Worth a closer look.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-182026-06-18open ↗8-KPeriod ending 2026-06-032026-06-03open ↗ARSPeriod ending 2025-12-312026-06-02open ↗DEF 14APeriod ending 2026-07-022026-06-02open ↗8-KPeriod ending 2026-05-292026-06-01open ↗DEFA14AFiling2026-05-26open ↗8-K/APeriod ending 2026-05-192026-05-26open ↗8-KPeriod ending 2026-05-192026-05-22open ↗EFFECTFiling2026-05-19open ↗EFFECTFiling2026-05-19open ↗10-QPeriod ending 2026-03-312026-05-15open ↗PRE 14APeriod ending 2026-05-082026-05-08open ↗
Frequently asked
- Is Transcode Therapeutics, Inc. (RNAZ) a buy?
- RNAZ currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.
- What is Transcode Therapeutics, Inc.'s quality score?
- RNAZ scores 33.61538461538461/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001829635, latest 10-Q filed 2026-05-15) · EODHD · as of 6/26/2026, 4:18:36 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.